Cholestech gets US thumbs-up for CRP test:
This article was originally published in Clinica
The US FDA has given Cholestech 510(k) market clearance to add a high sensitivity C-reactive protein (hs-CRP) blood test to the menu of assays run on its LDX tabletop analyser. The test, the first immunoassay developed for use on the analyser, can help doctors assess arterial inflammation and risk of heart disease. Laboratories will be able to use the test on the LDX system following the completion of a simple software upgrade, says the Hayward, California firm. Cholesterol and liver enzyme tests are already available for use on the analyser.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.